How “Breakthrough: Medical Findings Disappear:
A Relative Risk (RR) of 1.0 would mean there was no benefit, and a number less than 1.0 indicates a health benefit, and a number greater than 1.0 indicates that the intervention is actually harmful. When there were only a little data available, fish oil looked like manna from heaven. But with new studies and more data, the beneficial effect has shrunk to almost nothing. The current best estimate of relative risk (bottom row of table) is 0.96, barely below 1.0. And the “confidence interval” (the range of numbers in parentheses), which is an indicator of how reliable the current estimate is, actually runs to a value slightly greater than 1.0.
Why does this happen? Small studies do a poor job of reliably estimating the effects of medical interventions. For a small study (such as Sacks’ and Leng’s early work in the top two rows of the table) to get published, it needs to show a big effect — no one is interested in a small study that found nothing. It is likely that many other small studies of fish oil pills were conducted at the same time of Sacks’ and Leng’s, found no benefit and were therefore not published. But by the play of chance, it was only a matter of time before a small study found what looked like a big enough effect to warrant publication in a journal editor’s eyes.

In studies with a small sample size, the subject population is typically hand selected. Each subject fits the strict criteria required by the proscriptive protocol. Thus, the study generates optimal results. Fast-forward to a study with hundreds of subjects and subjects, who would have never been considered for the small study, are enrolled almost without a second guess. The larger study includes a population that is more representative of those who will use the intervention, provides a truer measurement of effectiveness, and, as a result, shows less effectiveness.